Policy | November 08, 2023
Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba
Lack of technology transfer stands out as a formidable barrier
Lack of technology transfer stands out as a formidable barrier
This product will be manufactured at Lupin’s Pithampur facility in India
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The initiative will focus on advocating for cleaner air
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
The companies plan to start a pivotal Phase 3 trial in the coming months
Syngene gains access to ERS Genomics' foundational CRISPR/Cas9 patent portfolio, ushering in a new era of technical innovation in India for its global partners
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Subscribe To Our Newsletter & Stay Updated
